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Background: It has been suggested that progestins may
have an inflammatory component and/or increase in pros-
taglandin synthesis. Thus, extended progestin use may be as-
sociated with higher risk of periodontal diseases. This study
investigates the association between depot medroxyproges-
terone acetate (DMPA) injectable contraception and the prev-
alence of periodontal diseases among US premenopausal
females.
Methods: Data for this cross-sectional analysis comes from
the 1999 to 2004 National Health and Nutrition Examination
Surveys. This analysis includes 4,460 US females (15 to 44
years of age) with complete DMPA usage and periodontal
status data.
Results: Current and past DMPA use was 4.1% and 12.0%,
respectively. The prevalence of gingivitis was 53.9% for fe-
males who reported having used DMPA compared with
46.1% for DMPA never-users. Females taking DMPA were
more likely to be young, single, and non-white, have a history
of smoking, have lower levels of education and income, and
have ‡1 live births and were less likely to visit the dentist. Using
logistic regression, DMPA use was associated with an increased
risk of gingivitis (odds ratio [OR] =1.7; 95% confidence interval
[CI] = 1.09 to 1.67) and periodontitis (DMPA, OR = 1.49; 95%
CI = 1.01 to 2.22) after adjusting for age, race, education, pov-
erty income ratio, dental care use, and smoking status. A signif-
icant interaction between smoking status and DMPA use was
also found (P = 0.029).
Conclusions: This study suggests that DMPA use may be as-
sociated with periodontal diseases. Additional investigation is
warranted as a result of the disproportionate usage of DMPA
among low-income populations who are at an increased risk
for poor dental health. J Periodontol 2012;83:1008-1017.
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H
ormonal contraceptives have been
reported to impact the oral health
of females.1,2 Oral contraceptives
primarily containing estrogen have been
associated with increased gingival in-
flammation and periodontitis, although
a consensus has not been reached in the
literature.3-6 Although less studied, pro-
gestin-only contraceptives, which contain
a synthetic version of the sex hormone
progesterone, may also impact periodon-
tal tissues.1,7,8 Progesterone has been
associated with changes in gingival and
other intraoral tissues in females, espe-
cially during life periods such as preg-
nancy.9-11 Furthermore, progesterone
has been shown to reduce corpuscular
flow rate, allowing for accumulation of
inflammatory cells, increased vascular
permeability,1,12 and increased vascular
proliferation.13,14
Depot medroxyprogesterone acetate
(DMPA) injectable contraceptioni is a
highly efficacious long-lasting progestin-
only injectable contraceptive. DMPA is
administered by intramuscular injection
every 3 months. A national study reports
that 3.0% to 12.0% of females in the
United States, 15 to 44 years old, use
DMPA.15 The contraceptive action of
DMPA results from its suppression of go-
nadotropin secretion, which in turn in-
hibits ovarian estradiol production and
prevents ovarian follicular maturation
and ovulation. In addition to prescribing
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DMPA for contraception, DMPA is used in the manage-
ment of abnormal uterine menstrual bleeding through
the prevention of the overgrowth of the uterine endo-
metrium.16,17 After 1 year of DMPA use (four injec-
tions), 50% of females experience amenorrhea.16
Females using this contraceptive method have
high levels of synthetic progestins and low circulating
endogenous estradiol levels, comparable to those
seen in the early follicular phase of a menstrual cycle
or postmenopause.18 With the suppression of ovarian
estradiol production, declines in bone mineral density
(BMD) at the hip and spine of DMPA users has been
shown to decrease by 0.5% to 3.5% after 1 year and
5.7% to 7.5% after 2 years of use compared with non-
users.19-22 Because of the skeletal health concerns,
a black box warning was issued by the US Food and
Drug Administration (FDA) stating that use should
be no longer than 2 years.23
Progestin-only contraceptive use has been associ-
ated with periodontal changes in adult females.1,7,24
Tilakaratne et al.8 observed that females who used
a progestin-only injectable contraceptive (DMPA) for
>2 years had significantly higher levels of gingival in-
flammationandclinical attachment loss (AL)compared
with non-users. In a clinical study by Seck-Diallo et al.,7
females using injectable progestin-only contraceptives
demonstrated more gingival inflammation, periodontal
pocketing, and AL than non-users. More recently, in
a prospective 6-month clinical study examining the
effect of the levonorgestrel implant on the periodon-
tium,1 females using the progestin implant contracep-
tives exhibited a statistically significant increase in
gingival probing depths (PDs) over the study period
compared with non-users. However, these studies have
important limitations, such as low number of DMPA
users, reporting DMPA use and oral contraceptive use
together, and lack of control for important periodontal
disease-associated confounders.
A suggested mechanism for the effect of DMPA on
periodontal tissues is that progestins in an active form
may stimulate the synthesis of prostaglandins, thereby
contributing to increased vascular permeability within
the chronically inflamed periodontium. Another possi-
bility is thatprogestinsmay promote tissue catabolism,
possibly resulting in increased AL.25,26 Because DMPA
suppresses estradiol concentrations, and estrogen
deprivation has been associated with tooth loss, alve-
olar bone loss, and AL, there is a possibility that the
drug could adversely affect the periodontal structures.
Many females of all social economic backgrounds
and ages use DMPA because of the convenience of
the method and contraceptive efficacy.15,27-29 How-
ever, approximately twice as many black females
use DMPA compared with white females.27 In addi-
tion, the majority of DMPA users are females of low
socioeconomic status who are already at risk for in-
creased levels of gingival disease.30 Given that DMPA
use is common among high-risk females, it is im-
portant to learn more about potential deleterious effects
on periodontal tissues. The objective of this analysis is
to determine if a progestin-only contraceptive¶ was as-
sociated with increased periodontal disease among fe-
males 15 to 44 years of age in the US population.
MATERIALS AND METHODS
Data Source
Data for this study were obtained from the 1999 to
2004 National Health and Nutrition Examination
Surveys (NHANES) public use datasets. The NHANES
are cross-sectional studies designed to obtain infor-
mation on the health and nutritional status of the
non-institutionalized population of the United States
conducted by the National Center for Health Statistics.
The sampling plan of each of the NHANES followed a
highly stratified multistage probability design in which
a sample of the US civilian, non-institutionalized pop-
ulation was selected to provide national estimates.
Methods for the standardized interviews, dental exam-
inations, and procedures for human protection and
consent have been described in detail previously.31
The number of records available for analysis varied
depending on the variables used.
Population
From the initial sample of 4,988 non-pregnant, pre-
menopausal females (aged 15 to 44 years), 4,462 re-
ceived periodontal examinations and had complete
DMPA use data. This age range was used for compa-
rability of data to existing National Survey of Family
Growth data. Data were excluded for females who in-
dicated the current use of oral contraceptives (n = 2).
Menopausal status was ascertained based on a respon-
dent’s report that her menstrual periods had not oc-
curred within the past 12 months or stopped entirely
(excluding females who were reported to be breast-
feeding or pregnant). In addition, 1,812 participants
had missing data in relation to other variables used
in the analysis; therefore, regression analyses models
were based on 2,648 females.
DMPA Use (Exposure to Sex Steroids)
The main exposure variable, DMPA use, was deter-
mined from two questions from the reproductive health
section of the examination interview conducted at the
mobile examination centers (MECs).31 The questions
were as follows: ‘‘Have you or respondent ever used
DMPA or injectables to prevent pregnancy?’’ and ‘‘Are
you/or the respondent now using DMPA or injectables
to prevent pregnancy?’’ The NHANES survey did not
¶ Depo-Provera, Pfizer Pharmaceutical Group.
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ask respondents about duration of DMPA use or age of
initiation of the contraceptive.
Measurement of Periodontal Conditions
All dental examinations were conducted by trained and
standardized examiners in dentalunits located in MECs.
The periodontal status of individuals in NHANES was
assessed using randomly assigned half-mouths (one
maxillary and one mandibular quadrant) for each in-
dividual using a periodontal probe.# There were slight
differences in the periodontal examination data be-
tween the different NHANES. The data from the 1999
to 2000 survey included AL and PD assessments at
two sites per tooth, and the gingival sweep was used
to assess gingival bleeding at the quadrant level. For
the 2001 to 2004 survey, periodontal assessments
were taken at three sites per tooth and were assessed
for PD, AL, and periodontal bleeding.32,33 For this
study, gingival bleeding was defined as the presence
or absence of gingival bleeding in ‡1 quadrants or ‡1
sites. Periodontal disease was defined as ‡2 sites with
AL = 4 mm and a PD ‡4 mm following previously pub-
lished reports.6,34
Sociodemographic Covariates
Sociodemographic and behavioral factors that have
been shown to be associated with DMPA use were eval-
uated for confounding and effect modification.Variables
obtained from the face-to-face interviews included
age, which was specified as both continuous and cat-
egorical, with six age categories. Race/ethnicity was
defined as non-Hispanic black, Hispanic, and non-
Hispanic white to allow comparisons with the National
Survey of Family Growth.15 Other race/ethnicities
were excluded from the analysis. Marital status was
defined as married (married or living together as mar-
ried) or not married. Poverty income ratio is the ratio
of reported family income category divided by the
poverty income threshold. Using the suggested cut
points from the NHANES III Analytic Guidelines,35
three categories, low, medium, and high, were created
for poverty index level in both datasets: 0.00 to 1.350,
1.351 to 3.500, and ‡3.501. Parity was collected from
the question ‘‘How many live births have you had?’’
Parity was coded as a categorical variable with cate-
gories being 0, 1 to 2, and ‡3 live births. Smoking sta-
tus was defined as never smoked (<100 cigarettes in
lifetime), former smoker (a positive answer to ever
smoked but do not smoke cigarettes now), and cur-
rent smoker (a positive answer to smoke now and
have smoked ‡100 cigarettes in a lifetime). Education
level was reported as <12 years of education, 12 years
of education, or >12 years of education.
Statistical Analyses
The NHANES involve complex sampling designs;
therefore, all statistical analyses were performed tak-
ing into account the effect of the study design as well
as incorporating the examination sampling weights.
The dependent variables for this analysis were gingi-
val bleeding and periodontal disease.
Univariate statistics were calculated for all variables
to describe the variables and their distributions along
with measures of unadjusted association between the
periodontaloutcomes (gingivalbleeding/periodontitis)
and other covariates of interest for the total sample.The
bivariate relationships between categorical variables
were assessed with the Pearson x2 test. The relation-
ships between continuous and categorical variables
were assessed with simple (unadjusted) linear regres-
sion models. Multiple logistic regression analysis using
the manual backward selection method was used to
assess the relationship between DMPA use and peri-
odontal outcomes while controlling for other covari-
ates. Because level of education and poverty index
were highly correlated, only poverty index was used
when generating the regression models.
Potential interactions between DMPA use and
smoking history were also examined. Because of
the complex interpretation associated with a three-
level variable (current, past, and never use) for both
DMPA exposure and smoking status, the interaction
term was recategorized into a cross product of a di-
chotomous variable of smoking history (ever versus
never) and DMPA use (ever versus never). The inter-
action term was not significant for the gingival bleed-
ing model; therefore, only the main effects model is
reported.
All analyses were conducted using a software
package** that can account for complex sampling
design and gives adjusted variance estimations.
Therefore, in all tables, the number of participants
per category is unweighted, whereas all means, per-
centages, and odds ratios (ORs) are weighted to re-
flect the target population and standard errors, and
95% confidence intervals (CIs) are adjusted for sam-
pling design.
RESULTS
The study sample included 4,460 non-pregnant, pre-
menopausal females, 15 to 44 years old, as shown in
Table 1. The distribution of the subpopulation was es-
timated to be 65.6% white, 51.4% well-educated (more
than a high school degree), and well-represented in
each of the poverty index levels; >57% were not mar-
ried, and 27.2% have never had a child. Approximately
4% were current DMPA users, whereas 12.1% indicated
a past history of DMPA use. Nearly one third of the re-
spondents indicated current smoking, 59.5% indicated
# NIDCR periodontal probe, National Institute of Dental and Craniofacial
Research, Bethesda, MD.
** Stata Data Analysis and Statistical Software v.11, StataCorp, College
Station, TX.
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a dental visit within the past 2 years. Using the study
definitions of periodontal disease, 54% had gingival
bleeding, whereas 10.6% had periodontitis.
Figure 1 shows the prevalence of DMPA use by age
andethnicity.Of the threeethnicitygroups,non-Hispanic
black females demonstrate the highest use at 22.9%.
When examining the ethnicity by age groups, young
non-Hispanic black females, 18 to 35 years old, re-
ported the highest use of the DMPA. For females >35
years old, a higher percentage of Hispanic females
Table 1.
Demographic Characteristics of Females (aged 15 to 44 years) by DMPA Use:
1999 to 2004 NHANES
Weighted % DMPA Use (mean – SE)
Variable Current (n = 157) Past (n = 553) Never (n = 3,750) Total (n = 4,460)*
Gingival bleeding
Yes 3.6 – 0.4 14.0 – 0.9 80.4 – 1.0 53.9 – 1.9
No 2.5 – 0.4 10.0 – 0.8 87.5 – 1.1 46.1 – 1.9
Periodontitis
Yes 2.3 – 0.4 12.3 – 1.0 85.4 – 1.1 10.6 – 1.7
No 3.3 – 0.5 8.1 – 0.9 88.6 – 1.0 89.4 – 1.7
Age (years)
15 to 19 4.2 – 0.8 5.0 – 0.7 90.8 – 1.0 16.3 – 0.4
20 to 29 4.7 – 0.7 17.6 – 1.4 77.7 – 1.5 30.9 – 0.9
30 to 39 1.8 – 0.4 11.8 – 1.3 86.4 – 1.5 34.2 – 0.8
40 to 44 1.4 – 0.4 5.6 – 1.3 92.0 – 1.3 18.5 – 0.6
Race
Non-Hispanic white 2.7 – 0.5 8.7 – 0.7 88.6 – 0.9 65.6 – 1.6
Hispanic 3.0 – 0.5 15.4 – 2.0 81.6 – 1.9 17.1 – 1.5
Non-Hispanic black 4.0 – 0.7 18.0 – 1.8 78.0 – 1.9 17.3 – 1.2
Education
Less than high school 4.3 – 0.6 13.2 – 1.2 82.5 – 1.4 26.1 – 0.7
High school 3.5 – 0.8 14.9 – 1.6 81.6 – 1.8 22.5 – 0.8
More than high school 2.1 – 0.5 8.9 – 0.8 89.0 – 0.9 51.4 – 1.0
Family poverty level
0 to 1.3 4.9 – 0.8 18.0 – 1.7 76.1 – 1.9 26.3 – 1.2
1.31 to 3.49 3.3 – 0.5 11.0 – 1.1 85.7 – 1.2 36.9 – 1.1
‡3.5 1.2 – 0.3 5.8 – 0.8 93.0 – 0.8 36.8 – 1.4
Marital status
Not married 3.7 – 0.4 11.5 – 0.9 84.8 – 0.9 57.2 – 1.1
Married/cohabitating 1.9 – 0.3 11.4 – 0.8 86.7 – 1.1 42.8 – 1.1
Parity (live births)
0 3.1 – 0.9 4.5 – 1.0 92.4 – 1.2 27.2 – 1.2
1 6.1 – 1.0 18.4 – 1.6 75.5 – 2.1 21.8 – 0.9
2 2.2 – 0.4 14.0 – 1.1 83.8 – 1.2 43.6 – 1.4
‡3 1.7 – 0.6 18.0 – 2.2 80.3 – 2.3 7.4 – 0.6
Dental visit <2 years
Yes 2.5 – 0.3 9.0 – 0.6 88.3 – 0.7 59.5 – 0.9
No 3.9 – 0.5 15.9 – 1.3 80.2 – 1.5 40.5 – 0.9
Smoking status
Current 3.6 – 0.9 17.4 – 1.3 79.0 – 1.7 30.2 – 1.0
Past 2.7 – 0.8 12.9 – 2.3 84.4 – 2.4 15.4 – 0.7
Never 2.4 – 0.3 10.6 – 0.9 87.0 – 0.9 54.4 – 1.2
All demographic factors differed significantly between the three DMPA user groups using a x2 test for association (P £0.003).
* Total sample weighted percents in column format.
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indicated use of DMPA, especially among the oldest
age group of 35 to 39 years.
Table 1 shows a summary of characteristics of the
sample by DMPA use. DMPA users were significantly
more likely to be young, non-white, among lower ed-
ucation and poverty levels, and have ‡1 child and
were less likely to have a dental visit within the past
2 years. The prevalence of gingivitis was significantly
associated with DMPA use. Current DMPA users were
more likely tohavegingivitis (3.6%versus2.5%),aswere
past DMPA users (14% versus 10%). Past users of DMPA
were more likely to have periodontitis (12.3% versus
8.1%), whereas current users were less likely to have
periodontitis.
Table 2 outlines the results from simple linear re-
gression analyses for periodontal conditions among
premenopausal adult US females, 15 to 44 years of
age, stratified by DMPA use. DMPA users were signif-
icantly younger than non-DMPA users (mean – SE,
25.1 – 0.58 versus 30.0 – 0.23 years; P = 0.001). Gin-
gival bleeding and PDs were significantly increased
among current and past DMPA users compared with
never-users. There was no significant difference in
the mean number of teeth among the contraceptive
groups.
The results of the logistic regression analyses pre-
sented in Table 3 indicate that, in general, females us-
ing DMPA have increased odds of poor gingival health.
In the unadjusted analysis, compared with non-DMPA
users, current users (OR = 1.91; 95% CI = 1.20 to 1.83)
and past users (OR = 1.43; 95% CI = 1.19 to 3.02) had
greater odds ofgingivitis.After adjusting for covariates,
including race, age, and dental use, these associations
remained significant for current DMPA use (OR = 1.73;
95% CI = 1.09 to 1.67). Comparing past users and non-
users, the prevalence was higher (logistic OR = 1.34;
95% CI = 0.98 to 2.67) for past users but did not reach
statistical significance. Hispanic and non-Hispanic
black females were estimated to have 39% to 50%
higher odds of having any periodontal disease com-
pared to non-Hispanic white females. In addition, both
lower poverty index levels and not having a dental visit
within the past 2 years resulted in an increased odds
of having gingivitis. Smoking history was not signif-
icantly associated with a higher odds of having gin-
givitis. The interaction between smoking status and
DMPA did not have a significant relationship with gin-
givitis (P = 0.46). Therefore, the main effects model is
presented without the dichotomous recategorization
Figure 1.
Females, aged 15 to 44 years, who reported ever usingDMPA byage and
race/ethnicity: 1999 to 2004 NHANES.
Table 2.
Periodontal Characteristics of Females (aged 15 to 44 years) by DMPA Exposure
(n = 4,460)
Periodontal Measure Current Use Past Use Never Use P value*
Number of females 157 553 3,750
Mean age (years) 25.1 – 0.58 28.6 – 0.29 30.0 – 0.23 0.001
Gingival bleeding (%) 5.2 – 0.97 3.54 – 0.38 2.9 – 0.23 0.01
PD >4 mm (%) 33.6 – 3.0 36.8 – 1.7 27.2 – 0.7 0.01
Max AL (mm) 1.6 – 0.06 1.7 – 0.04 1.3 – 0.02 0.04
Mean AL (mm) 0.40 – 0.04 0.46 – 0.02 0.44 – 0.02 0.35
Max PD (mm) 2.2 – 0.09 2.4 – 0.06 2.0 – 0.04 0.04
Mean PD (mm) 1.0 – 0.06 0.96 – 0.03 0.90 – 0.02 0.04
Mean number of teeth 27.7 27.8 27.3 0.43
Results are shown as mean – SE; Max = maximum.
* Comparisons were performed using simple unadjusted linear regression.
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of smoking, and DMPA use as the collapsed variables
did not show differences between current and past
DMPA users with respect to increased risk of gingival
inflammation.
The results of the logistic regression model exam-
ining the association of DMPA use with periodontal
disease are presented in Table 4. A significant inter-
action between smoking status and DMPA use was
found using the collapsed categorization of the two
variables discussed above. There was a significant
association between periodontal disease and race
(specifically, non-Hispanic blacks compared with
non-Hispanic whites), poverty index levels, age, and
not having a dental visit within the past 2 years.
The interaction between smoking status and DMPA
use is shown in Table 5. For those females who indi-
cated never smoking, ever (current/past) use of DMPA
was associated with an increased odds of having
periodontal disease compared with females who
indicated never use of DMPA (OR = 1.49; 95% CI =
1.01 to 2.22). For females that never used DMPA, re-
spondents who indicated ever (current/past) smoking
have an increase odds of having periodontal diseases
compared with those who never smoked (OR = 1.71;
95% CI = 1.26 to 2.38). For those females with a his-
tory of ever smoking and a history of ever DMPA use,
the odds of having periodontal diseases decreased
(OR = 0.55; 95% CI = 0.32 to 0.93).
DISCUSSION
In 2004, the FDA added a ‘‘black box’’ into the package
labeling for the injectable contraceptive DMPA warning
about bone health, indicating that use of DMPA for >2
years may increase bone loss and put females at risk
for osteoporotic fractures.36 Furthermore, there is evi-
dence that progestin-only contraceptives may affect
periodontal health.1,7,8 Hence, the aim of this study is
to investigate the association between DMPA and peri-
odontal diseases using a representative sample of US
females 15 to 44 years of age. This study suggests that
DMPA use may be associated with an increase in adverse
periodontal changes: gingival bleeding and periodontitis.
A significant association between current DMPA use
and gingival bleeding was observed after controlling
Table 3.
Logistic Regression Model for Gingival Bleeding: Odds of Having Gingival Bleeding Among
US Females (aged 15 to 44 years) 1999 to 2004 NHANES (n = 2,648)
Variable Unadjusted OR 95% CI Adjusted OR* 95% CI
DMPA use
Current 1.91 1.20 to 1.83 1.73 1.09 to 1.67
Past 1.43 1.19 to 3.02 1.34 0.9 8 to 2.67
Never 1 NA 1 NA
Age (years)
15 to 19 0.95 0.83 to 1.13 1.02 0.69 to 1.50
20 to 29 0.87 0.73 to 1.10 0.95 0.66 to 1.37
30 to 39 0.96 0.66 to 0.96 0.89 0.61 to 1.30
40 to 44 1 NA 1 NA
Race
Non-Hispanic black 1.50 1.08 to 2.07 1.50 1.08 to 2.07
Hispanic 1.39 1.04 to 2.19 1.39 1.04 to 2.19
Non-Hispanic white 1 NA 1 NA
Poverty index level
0 to 1.3 1.81 1.45 to 2.26 1.50 1.10 to 2.08
1.31 to 3.49 1.25 1.07 to 1.45 1.01 0.59 to 1.73
‡3.5 1 NA 1 NA
Dental visit <2 years
Yes 1.91 1.59 to 2.11 1.80 1.59 to 2.11
No 1 NA 1 NA
Smoking status
Current 0.90 0.69 to 1.18 1.00 0.76 to 1.32
Past 1.06 0.90 to 1.25 1.15 0.77 to 1.71
Never 1 NA 1 NA
* Model adjusted for age, race, poverty income level, dental visit, and smoking status.
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for potential confounding variables (OR = 1.73; 95%
CI = 1.09 to 1.67). A similar trend was observed for
past DMPA users but failed to reach the significance
level of P <0.05 (P = 0.057). To the best of our knowl-
edge, this is the first study to examine DMPA use and
periodontal conditions using multivariable modeling
to control for potential confounders, providing ad-
ditional evidence of an association between DMPA
use and gingival changes.
Using clinicalperiodontal measures, the study found
significant differences in PDs, gingival bleeding, and
AL between DMPA users and non-users. The increased
PDs among DMPA users is similar to previous small
clinical studies1,7 that found females using the pro-
gestin implant contraceptivesexhibited a statistically
significant increase in gingival PDs compared with
non-users. As in the study by Tilakaratne et al.,8 the
present study found statistically increased AL in DMPA
users compared with non-users. Interestingly, for our
population, the mean PDs were much lower compared
with the abovementioned studies. Users of DMPA in
this sample may be younger, but because the above
Table 4.
Logistic Regression Model for Periodontitis: Odds of Having Periodontitis Among US
Females (aged 15 to 44 years) 1999 to 2004 NHANES (n = 2,648)
Variable Unadjusted OR 95% CI Adjusted OR* 95% CI
DMPA use
Ever 1.62 1.27 to 1.92 1.49 1.01 to 2.22
Never 1 NA 1 NA
Race
Non-Hispanic black 1.51 1.17 to 1.82 1.45 1.00 to 2.11
Hispanic 1.34 1.06 to 1.71 1.39 0.96 to 2.01
Non-Hispanic white 1 NA 1 NA
Age (years)
20 to 29 1.71 1.36 to 2.15 1.65 1.00 to 2.62
30 to 39 3.52 2.81 to 4.54 2.43 1.89 to 3.18
40 to 44 5.82 4.61 to 7.52 4.38 3.20 to 6.01
15 to 19 1 NA 1 NA
Poverty index level
0 to 1.3 2.32 1.33 to 3.20 1.70 1.16 to 2.47
1.31 to 3.49 1.86 1.66 to 2.55 1.51 1.19 to 1.91
>3.5 1 NA 1 NA
Dental visit <2 years
Yes 1.59 1.38 to 1.83 1.44 1.18 to 1.76
No 1 NA 1 NA
Smoking status
Ever 1.67 1.43 to 1.93 1.71 1.26 to 2.38
Never 1 NA 1 NA
DMPA use · smoking interaction† 0.49 0.30 to 0.79 0.55 0.32 to 0.93
* Model controls for age race, poverty index level, smoking status, and dental visits.
† Interaction term model for DMPA use (ever/never) and smoking (ever/never).
Table 5.
Odds of Periodontal Disease Associated
With Smoking History According to DMPA
Use Among US Females (aged 15 to 44
years) 1999 to 2004 NHANES
Variable Adjusted OR* 95% CI
Never DMPA use and no smoking 1 NA
Ever DMPA use and no smoking 1.49 1.01 to 2.22
Never DMPA use and smoking† 1.71 1.26 to 2.38
Ever DMPA use and smoking† 0.55 0.32 to 0.93
* Model controls for age, race, poverty index level, smoking status, and
dental visits.
† Smoking is defined as ever (current/past).
Depot Medroxyprogesterone Acetate and Periodontal Health Volume 83 • Number 8
1014
studies did not disclose the age of their population, it is
difficult to make comparisons.
As the adjusted logistic regression model from
Table 4 indicates, DMPA use has a modest association
with the increased oddsofperiodontal disease.High sys-
temic progestin levels associated with the use of DMPA
have been shown to reduce skeletal BMD levels.22 Re-
cent reports37,38 suggest that the BMD deficits are
completely reversed within 1 to 3 years after discon-
tinuation of the contraceptive. Because the majority of
DMPA users are very young, this may allow for bone
recovery without deleterious effects occurring in
the periodontium.
The current analysis suggests that there is a strong
interaction between smoking status and DMPA use on
the prevalence of periodontal disease among females.
Surprisingly, among DMPA users, smoking appears
to decrease the risk for periodontitis. Because smok-
ing is considered a risk factor for periodontal diseases,
these results are puzzling. DMPA use and smoking may
not synergistically increase the risk of periodontitis, and
it can be speculated that smoking and DMPA may
mask each other’s effect on periodontitis. Accurate clin-
ical diagnosis of periodontal disease has been shown to
be difficult in smokers because of decreased gingival
inflammation, bleeding on probing, and obstruction of
periodontal probe penetration at the pocket base during
examination.39 Additional studies are needed to clarify
this relationship and the possible effect modification of
smoking on DMPA use and periodontal disease.
The sociodemographic composition of DMPA
users in our study is similar to the National Survey
of Family Growth estimates for contraceptive choices
in females 15 to 44 years old in the United States.28
The majority of DMPA users are young, non-white fe-
males of low socioeconomic status, who are more
likely to smoke. Our prevalence estimates are consis-
tent with those of Brunner Huber and Huber,40 who
showed that Hispanic females have a higher preva-
lence of DMPA use among those 35 to 44 years old.
Furthermore, we found that females who use DMPA
were more likely to smoke than females who had never
used DMPA contraception. Females who smoke have
been shown to be more likely to use implants, inject-
able contraceptives, and hormonal patches compared
with non-smokers.40 These same groups are dispro-
portionately at higher risk for gingival bleeding and
other periodontal diseases.30,41 Significantly fewer
current DMPA users reported visiting a dentist within
the past 2 years compared withnon-users (2.5%versus
4.0%), thus potentially increasing the risk of poor oral
health among these females.
Compared with previous studies of this association,
strengths of the current study include a large nationally
representative sample that provides greater general-
izability of findings across race/ethnicity and age
groups compared with periodontal-based samples
and detailed covariate information. Furthermore, the
use of multiple logistic regression models allowed us
to control for potential confounders, increasing the
validity of our outcomes.
Although the logistic model examining the increase
in the prevalence of periodontitis with DMPA use dem-
onstrated only a modest association, an increased
risk attributable to the use of an injectable contracep-
tive requires additional evaluation. Eke et al.42 re-
ported recently that the partial-mouth periodontal
examinations used in the NHANES produce under-
estimation of the prevalence of periodontal disease
resulting in disease misclassification. The small num-
ber of DMPA users coupled with the young age of
the population and the ensuing small number of peri-
odontal cases may have affected our ability to effec-
tively capture the association between DMPA use and
periodontal disease. Furthermore, progestins, syn-
thetic versions of the hormone progesterone, are used
for both contraception and to treat dysfunctional uterine
bleeding. Therefore, females using DMPA for uterine
bleeding may have different population characteristics
than younger females who use DMPA for contraceptive
purposes. These factors could lead to non-differential
misclassification among those who use DMPA and
those who do not, thus attenuating the strength of
the association identified in the analysis and there-
fore suggesting that the associations identified in this
study may be even stronger than reported here.
This studywassubject toanother limitation.NHANES
did not ask questions about the duration of DMPA use
or age of initiation of the contraceptive. Consequently,
we cannot determine the dose response between
DMPA duration and periodontal diseases. Another
limitation was the cross-sectional nature of the data. Be-
cause DMPA use and periodontal status were measured
at one point in time, it is impossible to know whether the
use of DMPA causes adverse periodontal changes. Fur-
thermore, unmeasured variables related to oral health
(oral hygiene measures, time since last pregnancy) or
other non-contraceptive use of DMPA use may have
influenced the results. Despite these limitations, this
study demonstrates that poor gingival health is associ-
ated with a progestin-only contraceptive.
CONCLUSIONS
Our study confirms and expands on the findings of
previous research to suggest that DMPA use influences
periodontal health. In addition, females who use DMPA
may be at increased risk for poor oral health as a result
of sociodemographic and lifestyle behavior factors.
Future clinical studies, including oral health behaviors
and duration of DMPA use, are required to evaluate the
relationship between DMPA use and the incidence of
periodontal diseases.
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